This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Economic Model Compares Iso-osmolar And Low-Osmolar Contrast Agents In Regard To Cost Associated With Contrast -Induced Acute Kidney Injury

Results of GE Healthcare-supported economic modeling of a retrospective meta-analysis of published literature were presented today at the SCAI 2014 Scientific Sessions in Las Vegas, NV. The model showed that iso-osmolar contrast media was associated with lower overall cost – nearly $700 savings per patient - when compared to low-osmolar contrast media in regard to contrast-induced acute kidney injury (CI-AKI). 1

“Contrast-induced acute kidney injury has major implications including morbidity and health resource utilization,” said Swapnil Hiremath, MD, Assistant Professor Medicine in the Division of Nephrology at the University of Ottawa and lead author of the study. “This study provides complementary and supportive CI-AKI data to the recently published meta-analyses by McCullough and Dong comparing contrast-induced nephrotoxicity of iso-osmolar and low-osmolar contrast media and ascribes an economic value to those analyses.” 2,3

About the Study

A systematic review and meta-analysis was conducted to estimate the risk of acute kidney injury after use of iso- and low-osmolar contrast media. A Markov model was then created, taking into account peri-procedural risks, the differential risk of acute kidney injury, the need for dialysis and subsequent mortality risk as well as cost associated with the contrast media itself and treatment for downstream clinical events.

The model showed that use of iso-osmolar contrast resulted in a higher quality adjusted life expectancy (29.19 versus 28.87 quality adjusted life years), in addition to nearly $700 savings per patient. This result was robust across most sensitivity analyses, including cost of contrast media, baseline risk of acute kidney injury, volume of contrast used, risk of dialysis. The exception was the sensitivity analysis with the differential risk of acute kidney injury with iso-osmolar versus low-osmolar contrast media.

“This study shows GE’s commitment to the continued advancement of scientific knowledge of iodinated contrast media choice in the interventional field, specifically highlighting health economics,” said Jan Makela, General Manager, Core Imaging, GE Healthcare Life Sciences. ”We were particularly pleased to find the model reported cost savings for iso-osmolar contrast even when taking into account upfront cost of contrast.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.01 0.33%
FB $103.05 1.10%
GOOG $687.62 0.66%
TSLA $150.25 -0.15%
YHOO $27.06 1.10%


Chart of I:DJI
DOW 15,891.35 +231.17 1.48%
S&P 500 1,847.08 +18.00 0.98%
NASDAQ 4,291.0070 +24.17 0.57%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs